CSE

Spirit Blockchain Completes Debt Settlement and Shares for Services Transaction

Retrieved on: 
Friday, November 10, 2023
Blockchain Capital, Indian stock exchange, Minority, CSE, Related party transaction, Bank statement, Debt settlement, NHS Shared Business Services, SPIR, Debt, Multilateral, Security (finance), Service, Share (finance)

Vancouver, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Spirit Blockchain Capital Inc. (CSE: SPIR) (the “Company” or “Spirit”) a leading digital asset investment firm‎, announces the following corporate updates:

Key Points: 
  • Vancouver, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Spirit Blockchain Capital Inc. (CSE: SPIR) (the “Company” or “Spirit”) a leading digital asset investment firm‎, announces the following corporate updates:
    The Company has settled outstanding indebtedness (the “Debt Settlement”) of the Company in the aggregate amount of ‎$36,500.00 (the “Debt”), pursuant to the terms of a debt settlement agreement with an arm’s length creditor (the “Creditor”).
  • In settlement of the Debt, the Company has issued $18,250.00 in cash and an aggregate of ‎456,250‎ common shares in the capital of the Company (the “Common Shares”) to the Creditor at a price of $0.04 per Common Share.
  • The Company has also issued an aggregate of ‎1,025,000‎ Common Shares at a price of $0.05 per Common Share to certain directors of the Company (the “Shares for Services”) .
  • The Shares for Services have been issued in lieu of cash payments for services rendered pursuant to consulting agreements whereby these individuals provided various management services to the Company.

Draganfly Announces Record Third Quarter Results of 2023

Retrieved on: 
Thursday, November 9, 2023
FSE, Research, Wildfire, CSE, UAV, EDGAR, GPS, Natural Resources, Flood, XL, Draganflyer X6, Workforce, Bank statement, Risk, Heavy lift, Geology, Recidivism, Commander, Prison, USD, United States Geological Survey, Data collection, PDT, Conference, Al-Tanf (U.S. military base), Super heavy-lift launch vehicle, SEDAR, Digital transformation, National security, NDAA, EDT, Cryptocurrency, Risk management, Saskatoon

Vancouver, BC., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its third quarter financial results.

Key Points: 
  • Vancouver, BC., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its third quarter financial results.
  • Gross profit for Q3 2023 was $894,683 up 42.7% from the same period last year primarily driven by higher product sales.
  • The Company recorded a comprehensive loss of $5,530,248 in the third quarter of 2023 compared to $4,992,533 in the same period of 2022.
  • Draganfly will hold a shareholder update and earnings call on November 9, 2023, at 2:30 p.m. PDT / 5:30 p.m. EDT.

ThreeD Capital Inc. Announces Unaudited October 31, 2023 Net Asset Value Per Share - $0.93

Retrieved on: 
Thursday, November 9, 2023
Bank statement, IDK, CSE, NAV, GAAP, Bank

TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that at October 31, 2023, its unaudited net asset value per share (“NAV”) was $0.93.

Key Points: 
  • TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that at October 31, 2023, its unaudited net asset value per share (“NAV”) was $0.93.
  • NAV is calculated based on unaudited month-end financial information.
  • Use of Non-GAAP Financial Measures:
    This press release contains references to NAV or “net asset value per share” which is a non-GAAP financial measure.
  • NAV is calculated as the value of total assets less the value of total liabilities divided by the total number of common shares outstanding as at a specific date.

Jones Soda Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
EBITDA, Jones Soda, Disclosure, CSE, OTCQB, Mary Jones, Running, Depreciation, Gateway Group, GAAP, Adjustment, Taste, Video game, Pharmaceutical industry

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones Soda” or the “Company”), the original craft soda known for its great taste, unconventional flavors and user-submitted photo labels, announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones Soda” or the “Company”), the original craft soda known for its great taste, unconventional flavors and user-submitted photo labels, announced its financial results for the third quarter ended September 30, 2023.
  • The third quarter of 2023 included approximately $220,000 in revenue from the Company’s Mary Jones cannabis business.
  • The Company’s cannabis brand, Mary Jones, generated approximately $220,000 in revenue in the third quarter of 2023 compared to approximately $400,000 in revenue in the second quarter of 2023 and approximately $114,000 revenue in the third quarter of 2022.
  • Jones Soda will hold a conference call today at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023.

Mountain Valley MD Announces Planned Appointment of New CFO Effective January 15, 2024

Retrieved on: 
Friday, December 15, 2023
Veterinary, Research, Vitamins, Supplements, Biotechnology, Health, Pharmaceutical, Agriculture, Science, Natural Resources, Acquisition, CSE, Bank, CFO, Executive, FRA, BofA Securities, Morgan Stanley, McGill University, Option, USD, CGMA, MBA, Chartered Global Management Accountant, Nankai University, Growth, Family, CNY, Initial public offering, Management, Biology, Far East

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of Yong Yao to the role of Chief Financial Officer effective January 15, 2024.

Key Points: 
  • Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of Yong Yao to the role of Chief Financial Officer effective January 15, 2024.
  • Ms. Letellier will continue to serve as the Company’s Chief Financial Officer until January 15, 2024 and assist with the transition to the new CFO.
  • The Company extends its appreciation to outgoing CFO Lucie Letellier for her contributions to the Company.
  • “We are grateful for her support of MVMD and willingness to manage through this transition window to minimize any potential disruption to the business.”

XTM Announces Proposed Offering of Securities

Retrieved on: 
Wednesday, December 13, 2023
Technology, Human Resources, Payments, Finance, Fintech, Banking, Professional Services, Digital Cash Management, Digital Assets, Software, Initial, Canadian Securities Exchange, Person, Indian stock exchange, CSE, Offering, Public expenditure, News, Security (finance)

XTM Inc. (“XTM” or the “Company”) (CSE:PAID; QB: XTMIF; FSE:7XT), announces that it has commenced a non-brokered private placement offering for aggregate gross proceeds of up to US$5,000,000 (the “Offering”) of units of the Company (each a “Unit”).

Key Points: 
  • XTM Inc. (“XTM” or the “Company”) (CSE:PAID; QB: XTMIF; FSE:7XT), announces that it has commenced a non-brokered private placement offering for aggregate gross proceeds of up to US$5,000,000 (the “Offering”) of units of the Company (each a “Unit”).
  • There can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or specific terms of the Offering.
  • The securities have not been and will not be registered under the United States Securities Act of 1933 (the “U.S.
  • Persons (as defined in the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

Québec Nickel Completes 2023 Exploration Programs at Its Ducros Nickel-Copper-PGE Project

Retrieved on: 
Wednesday, December 13, 2023
Mining, Minerals, Natural Resources, FSE, DUSC, CSE, Goldspot, Anomaly, Lifting, Exercise, Artificial intelligence, University, Geology, Multimedia, Algorithm, Donald Duck filmography, ALS, IOS, News, Nickel, Ore, AI, QNI, HQ, McMasterville, Quebec, Copper, Rare-earth element, Ducros

Québec Nickel Corp. ( CSE: QNI ; FSE: 7lB ; OTCQB: QNICF) (“QNI” or the “Company”) reports the completion of its 2023 exploration programs at its 100% owned Ducros Property, located 85 kilometers northeast of Val-d’Or, Québec.

Key Points: 
  • Québec Nickel Corp. ( CSE: QNI ; FSE: 7lB ; OTCQB: QNICF) (“QNI” or the “Company”) reports the completion of its 2023 exploration programs at its 100% owned Ducros Property, located 85 kilometers northeast of Val-d’Or, Québec.
  • (Graphic: Business Wire)
    Summary of 2023 Work Programs & Results:
    David Patterson, QNI’s CEO and Chairman, comments “I want to congratulate and thank the Ducros project team for accomplishing so much work during the year.
  • In parallel with the AI targeting project, ALS GoldSpot also completed a litho-structural reinterpretation of the Ducros Property.
  • In March 2023, Québec Nickel commissioned BluMetric Environmental, of St-Laurent Québec, to complete a baseline description of the hydrological and biological characteristics of QNI’s Ducros property and surrounding lands.

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease

Retrieved on: 
Thursday, December 7, 2023
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, NDA, CSE, Food, Patient, Cognition, ACOG, New Drug Application, Therapy, Insomnia, PDUFA, Galantamine, Pharmaceutical industry

The NDA has been granted a Prescription Drug User Fee Act (PDUFA) goal date of July 27th, 2024.

Key Points: 
  • The NDA has been granted a Prescription Drug User Fee Act (PDUFA) goal date of July 27th, 2024.
  • The NDA submission is based on results from four studies the Company conducted demonstrating bioequivalence for ALPHA-1062 to galantamine and galantamine ER.
  • “The FDA’s acceptance of our NDA for ALPHA-1062 brings us another significant step closer to delivering a much-needed treatment to patients suffering from Alzheimer’s Disease,” said Michael McFadden, Chief Executive Officer of Alpha Cognition.
  • “We look forward to continuing our collaboration with the FDA throughout the review process.”

Lobe Sciences Provides Update on L-130 Clinical Program

Retrieved on: 
Thursday, December 7, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Psilocybin, Absorption, Safety, CSE, OTCQB, Plasma, Tmax, Pharmacokinetics, Conference, Cognition, Human, Cmax, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead clinical program, L-130, a proprietary stabilized psilocin conjugate drug candidate.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead clinical program, L-130, a proprietary stabilized psilocin conjugate drug candidate.
  • The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose.
  • All subjects were evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28.
  • The study confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable, capsule over its inactive prodrug, psilocybin.

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Retrieved on: 
Tuesday, December 5, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, QCL, Psilocybin, Human, Patient, CSE, OTCQB, Partnership, Conference, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation.
  • The Company believes the updated stability report for L-130 is significant, as to date, no manufacturer of psilocin has reported a formulation of psilocin stable enough to be administered in a shelf-stable orally available formulation.
  • “L-130 was designed in collaboration with Quality Chemical Laboratories (QCL) based on the needs for a shelf stable oral molecule that can consistently deliver psilocin directly, therefore eliminating the inconsistencies and variabilities seen with psilocybin.
  • This is principally due to psilocybin’s need for first-pass metabolism” stated Philip Young, Chairman and CEO of Lobe Sciences.